WHO ICTRP trial
TALAPRO 1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With…
NL-OMON53009 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON53009 |
|---|---|
| Public title | TALAPRO 1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) |
| Scientific title | TALAPRO 1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone… |
| Primary sponsor | Pfizer Inc. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Australia;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Hungary;Italy;Korea (the Republic of);Netherlands;Poland;Spain;United Kingdom;United States of America |
| Conditions | Metastatic Castration Resistant Prostate Cancer Metatastic Castration Resistant Prostate Cancer and advanced Prostate Cancer;Metatastic Castration Resistant Prostate Cancer and advanced Prostate Cancer |
| Interventions | Talazoparib capsules 1 mg/day orally will be administered until radiographic progression ;DNA repair defects;Parp inhibitor;Prostate Cancer;Talazoparib |
| Registration date | Nov 30, 2022 |
| Target size | 5 |
| Secondary IDs | 2016-002036-32;NL59035.091.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: